PMEF
SRPT icon

Point72 Middle East FZE’s Sarepta Therapeutics SRPT Stock Holding History

Point72 Middle East FZE’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,150
Closed -$1.39M – 1849
2023
Q2 		$1.39M Sell
12,150
-8,880
-42% -$1.15M 0.04% 487
2023
Q1 		$2.9M Buy
+21,030
New +$2.73M 0.1% 255

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Point72 Middle East FZE's SRPT Position: Q3 2023 in Review

Point72 Middle East FZE sold out of Sarepta Therapeutics (SRPT) in Q3 2023, closing a stake of 12,150 shares — an estimated $1.39M sold.

Point72 Middle East FZE first reported a position in SRPT in Q1 2023 and held it in 2 quarters. The position peaked at $2.9M in Q1 2023. 394 funds tracked by Wall St. Rank hold SRPT as of Q3 2023.

  • Point72 Middle East FZE reported no remaining Sarepta Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 12,150 Sarepta Therapeutics shares in Q3 2023, an estimated $1.39M.
  • Point72 Middle East FZE first reported a position in Sarepta Therapeutics in Q1 2023 and held it in 2 quarters.
  • Point72 Middle East FZE's Sarepta Therapeutics position peaked at $2.9M in Q1 2023.
  • 394 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.